Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: a general overview.

• Viola, P. ^[1] ; Testa, V. ^[1] ; Ferro Desideri, L. ^{[2] [4]} ; Di Cello, L. ^{[2] [4]} ; Rutigliani, C. ^[3] ; Vagge, A. ^{[2] [4]} ; Nicolo, M. ^{[2] [4]} ; Cian, R. ^[1] ; Traverso, C.E. ^{[2] [4]}
  1. [1] Ospedale San Bortolo

     Ospedale San Bortolo

     Vicenza, Italia

     
  2. [2] University of Genoa

     University of Genoa

     Genoa, Italia

     
  3. [3] IRCCS Ospedale San Raffaele, University Vita-Salute, Milan, Italy
  4. [4] University Eye Clinic of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

  Mostrar afiliaciones +
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 57, Nº. 11, 2021, págs. 689-697
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Anti-vascular endothelial growth factors currently are the first-line treatment option for neovascular age-related macular degeneration (nAMD) and other retinal vascular disorders, and their clinical use is associated with high financial burden. Biosimilars are a type of biological product highly similar to referral biologic drugs; they are increasing competition among biologics and have the potential to reduce the overall expenditures on biologics. In this comprehensive literature review, the current investigational biosimilars acting on retinal diseases are discussed. The authors review the results of clinical studies and highlight ongoing trials. Several biosimilar candidates are under evaluation and the pipeline will rapidly change in the future, as soon as each patent expires. Clinicians have to know these new therapeutic agents, which might come in the mainstream clinical practice as a more cost-efficient option.